Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

FDA approves J&J's Bluetooth blood glucose monitor

Licenses iPhone, iPad and iPod Touch compatible monitoring system

LifeScan bluetooth blood glucose monitorA first-of-its-kind monitoring system that automatically sends blood glucose results via Bluetooth to an iPhone, iPad or iPod Touch has received clearance from the US Food and Drug Administration (FDA).

The OneTouch Verio Sync blood glucose monitoring system is marked by Johnson & Johnson's (J&J) LifeScan unit and uses a mobile app to enable it to communicate with Apple's iOS devices.

Ty Lee, vice president of marketing for LifeScan, said: "For so many people, their iPhone, iPad or iPod Touch have become a tool of choice to help organise and take charge of their daily lives.

"For people with diabetes, the new OneTouch Verio Sync System will enable them to use their iOS device to view and share their blood glucose results wirelessly, in much the same way they rely on them in other areas of their lives."

The system's OneTouch Reveal mobile app also allows users to view a variety of personalised information directly on their iPhone, iPad or iPod Touch.

This includes a 14-day summary of blood sugar test results and simple visuals showing the percentage of test results within target range, and the information can easily be shared via email or text with their care providers, family or friends.

FDA clearance for the OneTouch Reveal puts J&J on a similar footing with Sanofi and its iPhone, iPad and iPod Touch-compatible blood glucose monitor iBGStar, which was launched in the US last May.

It remains to be seen how users and healthcare professionals will view the devices' respective feature sets, not to mention whether a Bluetooth-enabled blood glucose monitor will be seen as more convenient than one that plugs directly into an iPhone or other Apple device.

5th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget....
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon....
Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...

Infographics